Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Herter-Sprie, Grit S., Buczkowski, Kevin A., Richards, William G., Gandhi, Leena, Redig, Amanda J. +18 more·2016·Nature Communications
DOI 10.1038/ncomms10501

Cited by (1,000)

Items 801–900 of 1,000

  1. Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
    Tuba Nur Gide, Inês Pires da Silva, Camelia Y. J. Quek, Peter M. Ferguson, Marcel Batten, Ping Shang, Tasnia Ahmed, Alexander Maxwell Menzies, Matteo Salvatore Carlino, Robyn P.M. Saw et al. · 2021 · Cancers
  2. Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations
    Marcin Niedbała, Katarzyna Malarz, Gitanjali Sharma, Gabriela Krämer-Marek, Wojciech Kaspera · 2022 · OncoTargets and Therapy
  3. Immunotherapy for Head and Neck Cancer
    Sumita Trivedi, Lova Sun, Charu Aggarwal · 2021 · Hematology/Oncology Clinics of North America
  4. The abnormal expression of Tim-3 is involved in the regulation of myeloid-derived suppressor cells and its correlation with preeclampsia
    Shuai Dong, Neelam Kumari Shah, Jin He, Shumei Han, Min Xie, Ying Wang, Tingting Cheng, Zitao Liu, Chang Shu · 2021 · Placenta
  5. Expression, prognostic significance and therapeutic implications of PD‐L1 in gliomas
    Gayaththri Vimalathas, Bjarne Winther Kristensen · 2021 · Neuropathology and Applied Neurobiology
  6. Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer
    Tomonari Kinoshita, Hideki Terai, Tomonori Yaguchi · 2021 · Life
  7. Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
    Natalia Krzyżanowska, Kamila Wojas‐Krawczyk, Janusz Milanowski, Paweł Adam Krawczyk · 2022 · International Journal of Molecular Sciences
  8. Synthetic and Biodegradable Molybdenum(IV) Diselenide Triggers the Cascade Photo‐ and Immunotherapy of Tumor
    Jiulong Zhao, Yao Zhang, Jing Zhang, Hang Wu, Jinfeng Li, Yizhou Zhao, Liying Zhang, Duowu Zou, Zhao‐Shen Li, Shige Wang · 2022 · Advanced Healthcare Materials
  9. Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer
    Qinying Sun, Xiangzhen Wei, Zhonglin Wang, Yan Yu Zhu, Weiying Zhao, Yuchao Dong · 2022 · Cancers
  10. Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma
    Hao Chen, Kyle H. Molberg, Kelley S. Carrick, Shuang Niu, Glorimar Rivera-Colón, Katja Gwin, Cheryl M. Lewis, Wenxin Zheng, Diego H. Castrillón, Elena Lucas · 2022 · Modern Pathology
  11. The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches
    Anita L. Kalluri, Pavan P. Shah, Michael K. Lim · 2023 · International Journal of Molecular Sciences
  12. Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC
    Jacob Gadwa, Maria Amann, Thomas E. Bickett, Michael W. Knitz, Laurel B. Darragh, Miles Piper, Benjamin Van Court, Sanjana Bukkapatnam, Tiffany Pham, Xiao‐Jing Wang et al. · 2023 · Cell Reports Medicine
  13. Interplay between inflammasomes and PD-1/PD-L1 and their implications in cancer immunotherapy
    Zhongyu Jiao, Jun Zhang · 2023 · Carcinogenesis
  14. Alternative immune checkpoints in immunoregulatory profile of cancer stem cells
    Keywan Mortezaee, Jamal Majidpoor · 2023 · Heliyon
  15. Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study
    Chia‐Chi Lin, Giuseppe Curigliano, Armando Santoro, Dong‐Wan Kim, David Wai-Meng Tai, Frank Stephen Hodi, Sofie Wilgenhof, Toshihiko Doi, Catherine A. Sabatos-Peyton, Sebastian Szpakowski et al. · 2024 · BMJ Open
  16. In situ vaccination with biocompatibility controllable immuno-sensitizer inducing antitumor immunity
    Heejun Shin, Kun Na · 2019 · Biomaterials
  17. Immunological and clinical implications of immune checkpoint blockade in human cancer
    Hyung‐Don Kim, Su‐Hyung Park · 2019 · Archives of Pharmacal Research
  18. My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer
    Alexander Levitzki, Shoshana Klein · 2019 · Proceedings of the National Academy of Sciences
  19. Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors
    Diwakar Davar, Hassane M. Zarour · 2019 · Methods in molecular biology
  20. Melanoma immunotherapy: strategies to overcome pharmacological resistance
    Claudia Trojaniello, Maria Grazia Vitale, Luigi Scarpato, Assunta Esposito, Paolo A. Ascierto · 2020 · Expert Review of Anticancer Therapy
  21. Evolving Role of Daratumumab: From Backbencher to Frontline Agent
    Ankur Jain, Karthik Ramasamy · 2020 · Clinical Lymphoma Myeloma & Leukemia
  22. Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy
    Lucas C. Adam, Junaid Y. Raja, Johannes Maximilian Ludwig, Adebowale Adeniran, Scott N. Gettinger, Hyun S. Kim · 2018 · Journal for ImmunoTherapy of Cancer
  23. Tumour Regression via Integrative Regulation of Neurological, Inflammatory, and Hypoxic Tumour Microenvironment
    Chang Hoon Lee, Jungsook Cho, Kyeong Lee · 2019 · Biomolecules & Therapeutics
  24. Role of Biofunctionalized Nanoparticles in Digestive Cancer Vaccine Development
    Razvan Septimiu Zdrehus, Cristian Delcea, Lucian Constantin MOCAN · 2024 · Pharmaceutics
  25. Single-cell multi-omics analysis reveals candidate therapeutic drugs and key transcription factor specifically for the mesenchymal subtype of glioblastoma
    Yufan Yang, Ziyuan Liu, Yerong Wei, Shuai He, Ancheng Gu, Zhiyong Li, Jianlong Li, Zhongyuan Xu, Bohong Cen · 2024 · Cell & Bioscience
  26. Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies
    Suman Giri, Gopal Lamichhane, Jitendra Pandey, Ramesh Khadayat, Sindhu KC, Hari Prasad Devkota, Dipendra Khadka · 2025 · International Journal of Molecular Sciences
  27. Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors
    Besan H. Al-Saafeen, Bassam R. Ali, Eyad Elkord · 2025 · Frontiers in Immunology
  28. Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential
    Reem Saleh, Salman M. Toor, Eyad Elkord · 2020 · Expert Opinion on Therapeutic Targets
  29. 5‐Aminolevulinic acid/sodium ferrous citrate enhanced the antitumor effects of programmed cell death‐ligand 1 blockade by regulation of exhausted T cell metabolism in a melanoma model
    Xin Hu, Weitao Que, Hiroshi Hirano, Zhidan Wang, Naoko Nozawa, Takuya Ishii, Masahiro Ishizuka, Hidenori Ito, Kiwamu Takahashi, Motowo Nakajima et al. · 2021 · Cancer Science
  30. TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy
    Kirsten De Ridder, Hanne Locy, Elisa Piccioni, Miren Zuazo, Robin Maximilian Awad, Stefaan Verhulst, Mathias Van Bulck, Yannick De Vlaeminck, Quentin Lecocq, Eva Reijmen et al. · 2022 · Frontiers in Immunology
  31. Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy
    Menghan Wu, Aijun Wu, Xiangrui Zhang, Yang Li, Beibei Li, Shengzhe Jin, Qingyu Dong, Xiaoshuang Niu, Lihan Zhang, Xiaowen Zhou et al. · 2023 · Biochemical Pharmacology
  32. Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor
    Jian Xu, Gan Chen, Sheng Yu, Senbang Yao, Wen Li, Huaidong Cheng · 2023 · Clinical Breast Cancer
  33. Strengthening the Combinational Immunotherapy from Modulating the Tumor Inflammatory Environment via Hypoxia‐Responsive Nanogels
    Wenhe Luo, Yanqiao Zeng, Qingle Song, Yu Wang, Feng Yuan, Qi Li, Yingnan Liu, Su Li, Nahar Jannatun, Guofang Zhang et al. · 2023 · Advanced Healthcare Materials
  34. Research progress and challenges of the PD-1/PD-L1 axis in gliomas
    Dong Jiacheng, Jiayue Cui, Guo Ying, Wang Shaohua, Liu Wenhui, Xinyu Hong · 2024 · Cell & Bioscience
  35. Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions
    Silvia Mara Baez Rodriguez, Ligia Gabriela Tătăranu, Amira Kamel, Șerban Turliuc, Radu Eugen Rizea, Anica Dricu · 2024 · International Journal of Molecular Sciences
  36. Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance
    Mark Owyong, Niloufar Hosseini-Nassab, Gizem Efe, Alexander T. Honkala, Renske J.E. van den Bijgaart, Vicki Plaks, Bryan Ronain Smith · 2017 · Drug Resistance Updates
  37. Liquid biopsy for lung cancer immunotherapy (Review)
    Liangliang Cai, Jie Wang · 2019 · Oncology Letters
  38. Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors
    Ke Ma, Qingqing Jin, Miao Wang, Xin Li, Yuyang Zhang · 2019 · Expert Review of Molecular Diagnostics
  39. Biological regulation of diacylglycerol kinases in normal and neoplastic tissues: New opportunities for cancer immunotherapy
    Javier Arranz‐Nicolás, Isabel Mérida · 2019 · Advances in Biological Regulation
  40. Acquired Resistance to Immune Checkpoint Blockade Therapies
    Xianda Zhao, Dechen Wangmo, Matthew J. Robertson, Subbaya Subramanian · 2020 · Cancers
  41. Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients
    Chaojun Liu, Zhen Zhang, Ping Yü, Guohui Qin, Kai Zhang, Nomathamsanqa Resegofetse Maimela, Lan Ji Huang, Shengli Yang, Yi Zhang · 2020 · Cancer Management and Research
  42. Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice
    Hui‐Ching Wang, Tsung‐Jang Yeh, Leong‐Perng Chan, Chin‐Mu Hsu, Shih‐Feng Cho · 2020 · International Journal of Molecular Sciences
  43. Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer
    Selina K. Wong, Wade Thomas Iams · 2021 · Cancers
  44. Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma
    Hema Dave, Madeline Terpilowski, Mimi Mai, Keri Toner, Melanie Grant, Maja Stanojevic, Christopher A. Lazarski, Abeer Shibli, Stephanie A. Bien, Philip Y Maglo et al. · 2021 · Blood Advances
  45. Role of Ezrin/Radixin/Moesin in the Surface Localization of Programmed Cell Death Ligand-1 in Human Colon Adenocarcinoma LS180 Cells
    Takuro Kobori, Chihiro Tanaka, Mayuka Tameishi, Yoko Urashima, Takuya Ito, Tokio Obata · 2021 · Pharmaceuticals
  46. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System
    Edmund K. Moon, Corey Jay Langer, Steven Μ. Albelda · 2017 · Annals of the American Thoracic Society
  47. Immunotherapy resistance: the answers lie ahead – not in front – of us
    Miles Cameron Andrews, Jennifer Ann Wargo · 2017 · Journal for ImmunoTherapy of Cancer
  48. Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?
    Sang Youn Hwang, Sangjune Laurence Lee, Hongqun Liu, Samuel S. Lee · 2023 · Liver Cancer
  49. Solid tumour-induced systemic immunosuppression involves dichotomous myeloid–B cell interactions
    Xiaoxin Hao, Yichao Shen, Jun Liu, Angela Alexander, Ling Wu, Zhan Xu, Liqun Yu, Yang Gao, Fengshuo Liu, Hilda L. Chan et al. · 2024 · Nature Cell Biology
  50. The response to anti–PD-1 and anti–LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming
    Annah S. Rolig, Xiyu Peng, Elizabeth R. Sturgill, Nisha Holay, Melissa J. Kasiewicz, Courtney Mick, Grace Helen McGee, William Miller, Yoshinobu Koguchi, Johanna Kaufmann et al. · 2025 · Science Translational Medicine
  51. Active aldehydes accelerate CD8+ T cell exhaustion by metabolic alteration in the tumor microenvironment
    Yasuharu Haku, Koji Kitaoka, Koki Ichimaru, T Hirano, Jun Wang, Kazuhiro Sonomura, Asuka Maruo, Shuhei Hirose, Yu Wang, Katsuhiro Ito et al. · 2026 · Nature Immunology
  52. Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy
    Martina Strudel, Lucia Festino, Vito Vanella, Massimiliano Beretta, Francesco Maria Marincola, Paolo A. Ascierto · 2019 · Current Medicinal Chemistry
  53. The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivo
    Tangwu Zhong, Chuanke Zhao, Shuntao Wang, Deshuang Tao, Shuxia Ma, Chengchao Shou · 2020 · Cancer Chemotherapy and Pharmacology
  54. Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma
    Natalia García‐Sancha, Roberto Corchado‐Cobos, Lorena Bellido-Hernández, Concepción Román‐Curto, Esther Cardeñoso Álvarez, Jesús Pérez‐Losada, Alberto Órfão, Javier Cañueto · 2021 · Cancers
  55. Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?
    Yuanwei Shi, Danting Tang, Xiaoqi Li, Xiaoli Xie, Yufu Ye, Lijuan Wang · 2022 · Frontiers in Oncology
  56. Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway
    Shuai Zheng, Kuojun Zhang, Xiangyu Zhang, Yibei Xiao, Tianyu Wang, Sheng Jiang · 2022 · Journal of Medicinal Chemistry
  57. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non–small cell lung cancer: A multiplex immunohistochemistry–based single-cell analysis
    Kohsuke Isomoto, Koji Haratani, Takahiro Tsujikawa, Yusuke Makutani, Hisato Kawakami, Masayuki Takeda, Kimio Yonesaka, Kaoru Tanaka, Tsutomu Iwasa, Hidetoshi Hayashi et al. · 2022 · Lung Cancer
  58. Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints
    Dharmindra Dulal, Andrew R. Boring, David Terrero, Tiffany L. Johnson, Amit Kumar Tiwari, Dayanidhi Raman · 2023 · Cancers
  59. Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT
    Katty Zeven, Timo W.M. De Groof, Hannelore Ceuppens, Robin Maximilian Awad, Thomas Ertveldt, Wout de Mey, Fien Meeus, Geert Raes, Karine Breckpot, Nick Devoogdt · 2023 · Frontiers in Immunology
  60. The role of programmed death receptor (PD‐)1/PD‐ligand (L)1 in periodontitis and cancer
    Sabine Elisabeth. Groeger, Joerg Meyle · 2024 · Periodontology 2000
  61. Immune-inflammatory modulation by natural products derived from edible and medicinal herbs used in Chinese classical prescriptions
    Qianming Kang, Luying He, Yang Zhang, Zhangfeng Zhong, Wen Tan · 2024 · Phytomedicine
  62. Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD‐1 antibodies
    Corinne A. Levingston, M. Young · 2017 · International Journal of Cancer
  63. Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy
    Shixue Chen, Lingling Li, Fan Zhang, Yu Wang, Yi Hu, Lei Zhao · 2019 · Journal of Immunology Research
  64. Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies
    Reham Ajina, David J. Zahavi, Yongwei Zhang, Louis M. Weiner · 2019 · Seminars in Cancer Biology
  65. Concurrent Injection of Unlabeled Antibodies Allows Positron Emission Tomography Imaging of Programmed Cell Death Ligand 1 Expression in an Orthotopic Pancreatic Tumor Model
    Jun Zhao, Xiaoxia Wen, Tingting Li, Sixiang Shi, Chiyi Xiong, Yanru Wang, Chun Li · 2020 · ACS Omega
  66. Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes
    Javier Arranz‐Nicolás, Miguel Martin-Salgado, Cristina Rodríguez‐Rodríguez, Rosa Liébana, María C. Moreno-Ortíz, Judith Maria Leitner, Peter Steinberger, Antonia Ávila‐Flores, Isabel Mérida · 2020 · Journal for ImmunoTherapy of Cancer
  67. Complex Interaction Among Immune, Inflammatory, and Carcinogenic Mechanisms in the Head and Neck Squamous Cell Carcinoma
    Ana Căruntu, Cristian Scheau, Mircea Ştefan Tampa, Simona Roxana Georgescu, Constantin Căruntu, Cristiana Tănase · 2021 · Advances in experimental medicine and biology
  68. Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
    Yong Jun Lee, Jii Bum Lee, Sang‐Jun Ha, Hye Ryun Kim · 2021 · Molecules and Cells
  69. The Balance between Differentiation and Terminal Differentiation Maintains Oral Epithelial Homeostasis
    Yuchen Bai, Jarryd Boath, Gabrielle R. White, U. G. I. U. Kariyawasam, Camile Selim Farah, Charbel Darido · 2021 · Cancers
  70. CD73/Adenosine Pathway Involvement in the Interaction of Non-Small Cell Lung Cancer Stem Cells and Bone Cells in the Pre-Metastatic Niche
    Giulia Bertolini, Mara Compagno, Dimas Carolina Belisario, Cristiano Bracci, Tullio Genova, Federico Davide Mussano, Massimo Vitale, Alberto L. Horenstein, Fabio Malavasi, Riccardo Ferracini et al. · 2022 · International Journal of Molecular Sciences
  71. Lack of MHC class II molecules favors CD8+T-cell infiltration into tumors associated with an increased control of tumor growth
    Nada Chaoul, Alexandre Tang, Belinda Desrues, Marine Oberkampf, Catherine Fayolle, Daniel Ladant, Alexander Sainz‐Perez, Claude Leclerc · 2017 · OncoImmunology
  72. The Immune Landscape of Non–Small-Cell Lung Cancer: Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures
    Jason Beattie, Lonny B. Yarmus, Momen M. Wahidi, M. Patricia Rivera, Christopher R. Gilbert, Fabien Maldonado, Kasia Czarnecka, Angela Christine Argento, Alexander Junxiang Chen, Felix J.F. Herth et al. · 2018 · American Journal of Respiratory and Critical Care Medicine
  73. Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial
    Meghan J. Mooradian, Florian Johannes Fintelmann, Thomas James LaSalle, Judit Simon, Alexander Graur, Alona Muzikansky, Mari A. Mino-Kenudson, Sophia Z. Shalhout, Howard L. Kaufman, Russell William Jenkins et al. · 2024 · Nature Communications
  74. Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements
    Alejandra Martínez‐Pérez, Rocío Granda‐Díaz, Candelaria Aguilar-García, Christian Sordo‐Bahamonde, Segundo R. Gonzalez · 2024 · Biomarker Research
  75. Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming
    Fanghua Chen, Yu Fu, Gaigai Bai, Junjun Qiu, Keqin Hua · 2025 · Frontiers in Pharmacology
  76. Addressing clinical needs in NSCLC immunotherapy: Mechanisms of resistance and promising combination strategies
    Kai Kang, Shanghai Liu, Zhuoran Yao, Jianxin Xue, You Lu · 2025 · Cell Reports Medicine
  77. Downregulation of Interferon-γ Receptor Expression Endows Resistance to Anti–Programmed Death Protein 1 Therapy in Colorectal Cancer
    Chunxiao Lv, Dongfen Yuan, Yanguang Cao · 2020 · Journal of Pharmacology and Experimental Therapeutics
  78. Evolution of Lung Cancer in the Context of Immunotherapy
    Sheng Yu, Ruilin Wang, Hong Tang, Lili Wang, Zhe Zhang, Sen Yang, Shuyue Jiao, Xuan Wu, Shuai Wang, Mingyue Wang et al. · 2020 · Clinical Medicine Insights Oncology
  79. Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer
    Avinash D. Khadela, Vivek P. Chavda, Humzah I. Postwala, Ramya Ephraim, Vasso Apostolopoulos, Yesha B. Shah · 2023 · Cancers
  80. Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study
    Yao-Ge Liu, Shitao Jiang, Lei Zhang, Han Zheng, Ting Zhang, Junwei Zhang, Haitao Zhao, Xinting Sang, Yiyao Xu, Xin Lu · 2023 · European journal of medical research
  81. Development of thiolated xanthan gum-stearylamine conjugate based mucoadhesive system for the delivery of biochanin-A to melanoma cells
    Mahima Jadav, Raghu Solanki, Sunita Patel, Deep Pooja, Hitesh Kulhari · 2023 · International Journal of Biological Macromolecules
  82. From antigen uptake to immune modulation: the multifaceted potential of peptide nanofibers as vaccine nanocarriers
    Hatem A. F. M. Hassan, Mohamed Aly Haider, Sherif Ashraf Fahmy · 2024 · Materials Advances
  83. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
    Anne Monette, Sarah Warren, J. Carl Barrett, Charlie Garnett‐Benson, Kurt Alex Schalper, Janis Marie Taube, Brian Gregory Topp, Alexandra Snyder · 2024 · Journal for ImmunoTherapy of Cancer
  84. Co‐inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma
    Liliana E. Lucca, David A. Hafler · 2017 · Immunological Reviews
  85. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics
    Meghan J. Mooradian, Ryan Joseph Sullivan · 2017 · Future Oncology
  86. From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely
    Daphne Day, Arta Monir Monjazeb, Elad Sharon, S. Percy Ivy, Eric H. Rubin, Gary L. Rosner, Marcus Otho Butler · 2017 · Clinical Cancer Research
  87. Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report
    Mario Alberto Occhipinti, Rosa Falcone, Concetta Elisa Onesti, Paolo Marchetti · 2018 · Drug Safety - Case Reports
  88. Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy
    Gagandeep Singh Brar, Tim F. Greten, Zachary J. Brown · 2018 · Therapeutic Advances in Gastroenterology
  89. Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
    NIKE Group, Marco Gallo, Valentina Guarnotta, Federica de Cicco, Manila Rubino, Antongiulio Faggiano, Annamaria Colao · 2019 · Journal of Cancer Research and Clinical Oncology
  90. Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient
    Irene Ghobrial, Calixto Hernández Cruz, Alfred L. Garfall, Nina D. Shah, Nikhil C. Munshi, Jonathan L. Kaufman, Lawrence Boise, Gareth John Morgan, Viktor A. Adalsteinsson, Salomon Manier et al. · 2019 · Clinical Lymphoma Myeloma & Leukemia
  91. Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy
    Naama Margolis, Ettai Markovits, Gal Markel · 2019 · Advanced Drug Delivery Reviews
  92. Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1
    Sean M. Hacking, Hector Chavarria, Cao Jin, Alexander C. Perry, Mansoor M. Nasim · 2020 · Pathology - Research and Practice
  93. Modulation of the Gut Microbiota Alters the Tumour-Suppressive Efficacy of Tim-3 Pathway Blockade in a Bacterial Species- and Host Factor-Dependent Manner
    Bokyoung Lee, Jieun Lee, Min-Yeong Woo, Mi Jin Lee, Ho‐Joon Shin, Kyongmin Hwang Kim, Sun Park · 2020 · Microorganisms
  94. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy
    Zhihui Kuang, Li Li, Pan Zhang, Bingliang Chen, Min Wu, Haiqing Ni, Shuai Yi, Jia Zou, Junjian Liu · 2020 · Antibody Therapeutics
  95. Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
    Małgorzata Bobrowicz, Radosław Zagożdżon, Joanna Domagała, Roberta Vasconcelos‐Berg, Emmanuella Guenova, Magdalena Winiarska · 2019 · Cancers
  96. Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance
    Shirin Attarian, Numa Rahman, Balázs Halmos · 2017 · Annals of Translational Medicine
  97. A novel and effective approach to generate germline-like monoclonal antibodies by integration of phage and mammalian cell display platforms
    Yu-jia Jin, Diao Yu, Xiaolong Tian, Huixian Li, Xiao-Chao Zhou, Yu Kong, Wei Zhang, Lu Zhang, Lei Cheng, Zhenlin Yang et al. · 2021 · Acta Pharmacologica Sinica
  98. Targeting the HVEM protein using a fragment of glycoprotein D to inhibit formation of the BTLA/HVEM complex
    Katarzyna Kuncewicz, Claire Battin, Katarzyna E. Wegrzyn, Adam K. Sieradzan, Anna Wardowska, Emilia Sikorska, Irma Giedrojć, Pamela Smardz, Michał Pikuła, Peter Steinberger et al. · 2022 · Bioorganic Chemistry
  99. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma
    Mahsa Pourhamzeh, Samieh Asadian, Hamed Mirzaei, Azita Minaei, Elahe Shahriari, Anastasia I. Shpichka, Hamidreza Aboulkheyr Es, Peter S. Timashev, Moustapha Hassan, Massoud Vosough · 2022 · Molecular and Cellular Biochemistry
  100. On-demand integrated nano-engager converting cold tumors to hot via increased DNA damage and dual immune checkpoint inhibition
    Xiaoqing Liu, Shuang Liang, Xiao Sang, Lili Chang, Shunli Fu, Han Kwang Yang, Huizhen Yang, Yongjun Liu, Na Zhang · 2022 · Acta Pharmaceutica Sinica B